|
|
IMS
Health reported a 5% growth (at
constant exchange) in drug sales to
$371.27 billion through retail pharmacies in the 13 key markets in the 12
month period from April 2005 through to April 2006.
- The single largest therapeutic sub
category in dollar sales continues to be the C10, hypolipidemia, class
selling $29.09 billion with a growth of 6.9% in the 12 months to April
2006. The second biggest group is the A2, anti-ulcerants, class at
$22.74 billion with a 2.9% growth.
- The best selling drug for the 12
months ending April 2006 was still Lipitor, worth over $11.43
billion, with a reduced growth at 4.9%. Nexium still has the
largest growth at the top with 16.2%. The five top drugs are 1.
Lipitor, 2. Nexium, 3. Plavix, 4. Zocor, 5. Seretide.
- The top five corporations in the year
to April 2006 are in order: 1. Pfizer, 2. GSK, 3. Norvartis, 4. Merck,
5. AstraZeneca.
|
